Pain Identified as Dominant Symptom in Long COVID

Pain Identified as Dominant Symptom in Long COVID

https://reachmd.com/news/pain-identified-as-dominant-symptom-in-long-covid/2467986/

Pain may be the most prevalent and severe symptom reported by individuals with long Covid, according to a new study led by UCL (University College London) researchers.

The study, published in JRSM Open, analysed data from over 1,000 people in England and Wales who logged their symptoms on an app between November 2020 and March 2022.

Pain, including headache, joint pain and stomach pain, was the most common symptom, reported by 26.5% of participants.

The other most common symptoms were neuropsychological issues such as anxiety and depression (18.4%), fatigue (14.3%), and dyspnoea (shortness of breath) (7.4%). The analysis found that the intensity of symptoms, particularly pain, increased by 3.3% on average each month since initial registration.

The study also examined the impact of demographic factors on the severity of symptoms, revealing significant disparities among different groups. Older individuals were found to experience much higher symptom intensity, with those aged 68-77 reporting 32.8% more severe symptoms, and those aged 78-87 experiencing an 86% increase in symptom intensity compared to the 18-27 age group.

Gender differences were also pronounced, with women reporting 9.2% more intense symptoms, including pain, than men. Ethnicity further influenced symptom severity, as non-white individuals with long Covid reported 23.5% more intense symptoms, including pain, compared to white individuals.

The study also explored the relationship between education levels and symptom severity. Individuals with higher education qualifications (NVQ level 3, 4, and 5 — equivalent to A-levels or higher education) experienced significantly less severe symptoms, including pain, with reductions of 27.7%, 62.8%, and 44.7% for NVQ levels 3, 4 and 5 respectively, compared to those with lower education levels (NVQ level 1-2 — equivalent to GCSEs).

Socioeconomic status, as measured by the Index of Multiple Deprivation (IMD), also influenced symptom intensity. Participants from less deprived areas reported less intense symptoms than those from the most deprived areas. However, the number of symptoms did not significantly vary with socioeconomic status, suggesting that while deprivation may exacerbate symptom intensity, it does not necessarily lead to a broader range of symptoms.

Lead author Dr David Sunkersing (UCL Institute of Health Informatics) said: “Our study highlights pain as a predominant self-reported symptom in long Covid, but it also shows how demographic factors appear to play a significant role in symptom severity.

“With ongoing occurrences of Covid-19 (e.g., LB.1, or D-FLiRT variants), the potential for more long Covid cases remains a pressing concern. Our findings can help shape targeted interventions and support strategies for those most at risk.”

In the paper, the researchers called for sustained support for long Covid clinics and the development of treatment strategies that prioritise pain management, alongside other prevalent symptoms like neuropsychological issues and fatigue.

Given the significant impact of demographic factors on symptom severity, the study underscored the need for healthcare policies that addressed these disparities, ensuring equitable care for all individuals affected by long Covid, the researchers said.

Study limitations included a lack of information on other health conditions participants may have had and a lack of information about health history. The researchers cautioned that the study may have excluded individuals with very severe Covid and those facing technological or socioeconomic barriers in accessing a smartphone app.

The study was led by the UCL Institute of Health Informatics and the Department of Primary Care and Population Health at UCL in collaboration with the software developer, Living With Ltd.

Oversight Chair Knocks PBM Execs for July Testimony Under Oath

Oversight Chair Knocks PBM Execs for July Testimony Under Oath

https://ncpa.org/newsroom/news-releases/2024/08/28/oversight-chair-knocks-pbm-execs-july-testimony-under-oath

Calls on them to provide any necessary corrections to the record within three weeks

Isn’t lying under oath called perjury? According to this article, three top execs of the 3 largest PBMs LIED under oath to the  House Committee on Oversight and Accountability

Chairman James Comer (R-Ky.) called on executives from Express Scripts, CVS Caremark, and OptumRx to correct the record for statements.

What kind of political BS is this, the law says a fine or FIVE YEARS IN PRISON. Those corporations will pay just about any fine that would be imposed. Each of those companies are worth hundreds of millions each.  Throw those 3 exec’s ass in JAIL FOR 5 YEARS and watch all those PBMs rapidly start changing their processes.  Repeal the   https://en.wikipedia.org/wiki/ McCarran%E2%80%93Ferguson_Act McCarran–Ferguson Act  gives the insurance industry an exemption to the Sherman Antitrust Act and then let the FTC have their way with the monopolistic practices of our insurance industry.

ALEXANDRIA, Va. (Aug. 28, 2024) – The National Community Pharmacists Association released the following statement from CEO B. Douglas Hoey, pharmacist, MBA, after House Committee on Oversight and Accountability

Chairman James Comer (R-Ky.) called on executives from Express Scripts, CVS Caremark, and OptumRx to correct the record for statements they made under oath during their appearance before the committee in July:

“PBM-insurers’ days of reckoning are continuing. Congress and the FTC aren’t falling for their nonsense, and the heat on them has never been higher. PBM-insurers exert so much influence on which drugs patients have access to and how much they cost that calling out their mistruths and working to hold them accountable is critical, and we applaud Chairman Comer for doing so. We also need to emphasize that Congress must absolutely pass PBM reforms this year. The time for waiting is over because PBM-insurers showed they will fudge the truth wherever they can and they’ll only change their ways if they are forced.”

In a statement released after the July hearing, Hoey called out

the excuses and at times downright lies the PBM executives were attempting to feed members of the committee about the roles their organizations play in increasing prescription costs and decreasing patient access to health care.  

Making sure to note that under the law,

those who are untruthful in committee testimony under oath run the risk of a fine or five years of imprisonment,

Comer’s letters to the PBM executives specifically highlight their statements that contradict the committee’s and the Federal Trade Commission’s findings about the PBMs’ self-benefitting practices that jeopardize patient care, undermine local pharmacies, and raise prescription drug prices; claims that they do not steer patients to PBM-owned pharmacies; and claims contradicting the committee’s and FTC’s findings regarding contract negotiations, contract opt-outs, and payments to pharmacies. The committee is asking the big three PBMs to provide their corrections to the record by Sept. 11, 2024.

Dr. Mark Ibsen describes his experience being targeted for treating pain

A teachable moment

I have been wanting to post about this but waited till there was some progress. Back the end of Jan 2024 Barb ended up having lumbar surgery. Her pain had reached a level that even upping her doses of opioids over several months could not suppress her increased pain.

She debated on having the surgery for several months before relenting to having it done. The Surgeon what we chose, was recommended by the surgeon that had done my partial knee replacement in mid-2023.

This surgeon is an employee of a very large and very well known and respected ortho surgeon group that has been around for maybe 5+ decades, and the practice is owned by one of the three major hospital system in a city that is the largest city in the state and there is also a nearby medical school.

Barb went back for a 6 weeks follow up. The surgeon seem to start off with THE INCISION IS INFECTED!  After we expanded our pharmacy into providing home medical equipment and then we started dealing with pts who were bed or wheelchair confined and experiencing “bed sores” and/or “decubitus ulcers“. Barb got the opportunity to get certified as a tissue therapist. So she could help pts and their caregivers try to prevent those decubitus ulcers and/or help them to heal those if they already had them. She knew the outwards signs if a broken skin, bedsore, surgical incision was infected, and I learned them via osmosis being married to her.  I knew from clinical standpoint what lab tests would suggest that the pt had an infected decubitus.  A infected decubitus typically had necrotic (dead) tissue around the perimeter, had a bad odor, their blood work should show elevated white blood cell count and pts would have at least a low grade elevated temp.

Barb’s labs nor her surgical incision showed any indication that it was infected, but the surgeon was insistent that he had to debride Barb’s incision STAT.. sent her directly from his office to the hospital and had her admitted. Two days later she was in surgery again. While Barb “survived” the surgery. The overall care that Barb received was no where ideal nor close to best practices and standard of care.

https://www.cms.gov/medicare/quality/quality-improvement-organizations

The above organization QIO, followups on complaints from Medicare pts and the pt’s care in a hospital environment.  I filed a complaint with this organization around the end of April 2024 and just got a return phone call from one of their representatives, as a follow up. This representative was basically quoting from the physician reviewer report/summary. First of all the ortho surgeon NEVER provided any of Barb’s medical records from his practice. The representative said that, my complaints would be forward on to CMS (Center for Medicare/Medicaid Services) to deal with the ortho surgeon’s lack of response of providing medical records.

Most of what I heard, was the reviewer could not document most of my complaints from the medical records from the various providers, starting with the hospital itself down to several vendors who provided Barb’s home services.

When all was said and done, the representative told me that I could have a second reviewer to look over my complaints and also said that I could add any more information.  I had provided them with 7-8 pages of  typed (word processor) detailed complaints and I told the representative that I felts that my complaint was VERY DETAILED!

There was a pause in the conversation and then the representative said “that is a good description”. I asked the representative that if I asked for another reviewer to look at my complaint that if I could ask that the reviewer focus on the what appeared to be that most of the medical documentation – IMO – did not come close to what I understand as what should be a standard of care and best practice.   The representative stated that she would state that and highlight it on my request for a second reviewer to evaluate the quality of medical records that were provided.

Apparently the jury is still out!

 

 

Don’t expect a medicare insurance broker to recommend Centene Medicare Part D prgm

Centene to end Part D broker payments

https://www.beckerspayer.com/payer/centene-ends-part-d-broker-payments.html

Centene will no longer pay commission to insurance brokers enrolling or renewing members in its Medicare Part D plans. 

In a message sent to brokers, published Aug. 25 on Pinnacle Financial Services, Centene said it will continue paying compensation to brokers enrolling members in its Wellcare Medicare Advantage plans. 

In its message, Centene said the Inflation Reduction Act has resulted in “significant changes” to Part D. 

“To continue providing access to high-quality healthcare and Part D coverage that helps families and individuals, we have made a difficult decision — effective Jan. 1, 2025 — to cease new and renewal commissions for PDP beginning with the 2025 plan year,” Centene wrote to brokers. 

In 2024, provisions of the Inflation Reduction Act that eliminate copays for Part D beneficiaries who enter the catastrophic phase of coverage took effect. In 2025, a $2,000 out-of-pocket spending cap will apply to Part D members. 

Medicare Advantage and Part D plans pay brokers compensation for new enrollments and renewals in their plans. 

Jessica Brooks-Woods, CEO of the National Association of Benefits and Insurance Professionals, said in an Aug. 27 statement the decision to cut commissions “threaten not only the livelihoods of Medicare agents but also the communities they serve and the seniors who rely on their expert guidance.” 

The association has reached out to Centene leaders, Ms. Brooks-Woods said, as the decision sets a precedent. 

“We invite the leaders to talk about how these decisions will affect Medicare beneficiaries and their families,” Ms. Brooks-Woods said. “We are asking important questions and looking at all possible options to make sure our seniors and their trusted partners are protected.” 

Centene was the fourth largest Medicare Part D plan sponsor in 2023, according to KFF. The company had 6.6 million Part D members as of June. 

The insurer will also exit six Medicare Advantage markets next year. Centene will no longer offer its Wellcare MA plans in Alabama, Massachusetts, New Hampshire, New Mexico, Rhode Island and Vermont, but will continue to offer prescription drug plans in those states.

Becker’s has reached out to Centene for comment and will update this article if more information becomes available. 

Are you in a healthcare desert or soon will be

Pharmacy Closures Disproportionately Affect Vulnerable Americans

https://www.uspharmacist.com/article/pharmacy-closures-disproportionately-affect-vulnerable-americans

Columbus, OH—How do so-called pharmacy deserts disproportionately affect U.S. residents living in regions with low healthcare practitioner supply and high social vulnerability?

That was the question raised in a recent research letter published in the Journal of the American Medical Association Network Open. “Retail pharmacy chains have been closing thousands of locations throughout the US, possibly playing a role in health care gaps,” the Ohio State University authors wrote. “Similar to the concept of food deserts, areas in which medications are harder to obtain have been deemed pharmacy deserts.”

The study team sourced data through 2020 from TelePharm Map on communities located 10 or more miles from the nearest retail pharmacy. Counties were stratified as high pharmacy desert density if the number of pharmacy deserts per 1,000 inhabitants was in the 80th percentile or higher.

At the same time, the researchers obtained social vulnerability index (SVI) and healthcare practitioner data from the Agency for Toxic Substances and Disease Registry and the Area Health Resources File.

The study calculated the density of primary care practitioners (PCPs; including family medicine, general practice, general internal medicine, general pediatrics physicians) as the number of PCP per 10,000 inhabitants.

The results indicated that, among 3,143 counties reviewed, 1,447 (46%) had at least one pharmacy desert, of which 818 (56.5%) were categorized as having low and 629 (43.5%) as having high pharmacy desert density, respectively.

“Counties with a high vs. low pharmacy desert density had a higher SVI (high SVI: 238 [38.0%] vs. 294 [36.0%]; low SVI: 194 [31.0%] vs 246 [30.0%]; P = .006),” according to the article. “Areas with a high pharmacy desert density had lower median [IQR (interquartile)] PCP density (3.65 [1.12-5.96]) vs. regions with low (5.01 [3.21-7.53]) or no pharmacy (4.86 [3.10-7.40) desert density (P <.001).”

On multivariate analysis, after controlling for age and sex, the researchers determined that both high SVI (odds ratio [OR], 1.35; 95% CI, 1.07-1.70; P = .01) and low PCP density (OR, 2.27; 95% CI, 1.80-2.86; P <.001) were associated with a higher likelihood for a county to have a high pharmacy desert density.

“In the U.S. CVS announced plans to close 900 stores in the next 3 years, and Rite Aid filed for bankruptcy,” the authors wrote. “As pharmacies close, more and more individuals are left without easy access to medications, with disproportionate consequences for certain communities. Patients in higher SVI counties with a lower PCP density had a 30% to 40% higher likelihood to reside in regions with pharmacy deserts.”

The researchers noted that their findings underscore how disparities compound to create barriers to access basic healthcare, noting the association between SVI and the number of chronic conditions.

“For example, diabetes and hypertension tend to be more prevalent among black patients living in rural areas,” the authors wrote. “Poor access to pharmacies is often associated with lower medication adherence. Patients in socially vulnerable communities may lack the means to travel to other pharmacies or may have limited access to broadband internet to find telepharmacy options. Furthermore, pharmacies often offer diagnostic, preventive, and emergency services.”

Complicating the situation is that high pharmacy desert density counties tend to also have a lower PCP density. “Patients residing in these regions face increased barriers to accessing primary health care needs,” the authors concluded.

The authors suggested that in future studies, weighted regression and inverse probability weighting could provide more insights into disparities in healthcare access.

That high SVI and low PCP density that were associated suggested that “people already at highest risk of being neglected by the health care system are most likely to be affected by pharmacy closures. More efforts are needed to maintain access to pharmacies in underserved communities.”

Eli Lilly selling Zepound vials at 50% discount: 4 notes

Guess how much the insurance/PBM industry was DEMANDING in a kickback/rebate/discount from Lilly for them to paid for this medication for one of their beneficiaries?

Eli Lilly selling Zepound vials at 50% discount: 4 notes

https://www.beckershospitalreview.com/pharmacy/eli-lilly-selling-zepound-vials-at-50-discount-4-notes.html

Eli Lilly has started selling single-dose vials of its blockbuster weight loss drug Zepbound for roughly half of its usual monthly list price. 

Patients with a prescription who are paying out of pocket can now purchase a month’s supply of the drug through LillyDirect ( https://lillydirect.lilly.com/ )— the company’s direct-to-consumer platform that launched in January. Eli Lilly is offering a four-week supply of 2.5-milligram and 5-milligram single-dose vials for $399 and $549, respectively. The list prices for GLP-1 weight loss drugs are typically around $1,000 a month.

This new option helps millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card program, those without employer coverage and those who need to self-pay outside of insurance,” Eli Lilly said in an Aug. 27 news release.

Three more notes:

  • Zepbound typically comes in a single-dose autoinjector pen. The new vials will require patients to administer the medicine using a needle and syringe. The drugmaker said the vials will expand the supply of Zebound in the U.S. because they are simpler to produce than the autoinjector pens.
  • Eli Lilly added a self-pay pharmacy channel to its LillyDirect website, where patients with a valid prescription can purchase the vials. The drugmakers said this will ensure patients receive “genuine” Zepbound amid a rise in counterfeit and compounded products, which use the same active ingredient as brand-name drugs but are not tested or regulated by the FDA.
  • The move stands to raise pressure on Novo Nordisk surrounding the prices of its GLP-1 drugs, analysts told Bloomberg. The drugmaker’s Ozempic is listed at $969 per month in the U.S., and Wegovy at $1,349 per month. The company’s CEO, Lars Fruergaard Jørgensen, is set to testify on the drug’s prices at a Senate Health, Education, Labor and Pensions Committee hearing Sept. 24. Mr. Jørgensen recently told NBC News the two drugs can reduce overall costs associated with obesity care.

Feds Killed Plan To Curb Medicare Advantage Overbilling After Industry Opposition

Feds Killed Plan To Curb Medicare Advantage Overbilling After Industry Opposition

https://kffhealthnews.org/news/article/medicare-advantage-overbilling-diagnostic-codes-cms-killed-rule/

A decade ago, federal officials drafted a plan to discourage Medicare Advantage health insurers from overcharging the government by billions of dollars — only to abruptly back off amid an “uproar” from the industry, newly released court filings show.

The Centers for Medicare & Medicaid Services published the draft regulation in January 2014. The rule would have required health plans, when examining patient’s medical records, to identify overpayments by CMS and refund them to the government.

But in May 2014, CMS dropped the idea without any public explanation. Newly released court depositions show that agency officials repeatedly cited concern about pressure from the industry.

The 2014 decision by CMS, and events related to it, are at the center of a multibillion-dollar Justice Department civil fraud case against UnitedHealth Group pending in federal court in Los Angeles.

The Justice Department alleges the giant health insurer cheated Medicare out of more than $2 billion by reviewing patients’ records to find additional diagnoses, adding revenue while ignoring overcharges that might reduce bills. The company “buried its head in the sand and did nothing but keep the money,” DOJ said in a court filing.

Medicare pays health plans higher rates for sicker patients but requires that the plans bill only for conditions that are properly documented in a patient’s medical records.

In a court filing, UnitedHealth Group denies wrongdoing and argues it shouldn’t be penalized for “failing to follow a rule that CMS considered a decade ago but declined to adopt.”

This month, the parties in the court case made public thousands of pages of depositions and other records that offer a rare glimpse inside the Medicare agency’s long-running struggle to keep the private health plans from taking taxpayers for a multibillion-dollar ride.

“It’s easy to dump on Medicare Advantage plans, but CMS made a complete boondoggle out of this,” said Richard Lieberman, a Colorado health data analytics expert.

Spokespeople for the Justice Department and CMS declined to comment for this article. In an email, UnitedHealth Group spokesperson Heather Soule said the company’s “business practices have always been transparent, lawful and compliant with CMS regulations.”

Medicare Advantage insurance plans have grown explosively in recent years and now enroll about 33 million members, more than half of people eligible for Medicare. Along the way, the industry has been the target of dozens of whistleblower lawsuits, government audits, and other investigations alleging the health plans often exaggerate how sick patients are to rake in undeserved Medicare payments — including by doing what are called chart reviews, intended to find allegedly missed diagnosis codes.

By 2013, CMS officials knew some Medicare health plans were hiring medical coding and analytics consultants to aggressively mine patient files — but they doubted the agency’s authority to demand that health plans also look for and delete unsupported diagnoses.

The proposed January 2014 regulation mandated that chart reviews “cannot be designed only to identify diagnoses that would trigger additional payments” to health plans.

CMS officials backed down in May 2014 because of “stakeholder concern and pushback,” Cheri Rice, then director of the CMS Medicare plan payment group, testified in a 2022 deposition made public this month. A second CMS official, Anne Hornsby, described the industry’s reaction as an “uproar.”

Exactly who made the call to withdraw the chart review proposal isn’t clear from court filings so far.

“The direction that we received was that the rule, the final rule, needed to include only those provisions that had wide, you know, widespread stakeholder support,” Rice testified.

“So we did not move forward then,” she said. “Not because we didn’t think it was the right thing to do or the right policy, but because it had mixed reactions from stakeholders.”

The CMS press office declined to make Rice available for an interview. Hornsby, who has since left the agency, declined to comment.

But Erin Fuse Brown, a professor at the Brown University School of Public Health, said the decision reflects a pattern of timid CMS oversight of the popular health plans for seniors.

“CMS saving money for taxpayers isn’t enough of a reason to face the wrath of very powerful health plans,” Fuse Brown said.

“That is extremely alarming.”

Invalid Codes

The fraud case against UnitedHealth Group, which runs the nation’s largest Medicare Advantage plan, was filed in 2011 by a former company employee. The DOJ took over the whistleblower suit in 2017.

DOJ alleges Medicare paid the insurer more than $7.2 billion from 2009 through 2016 solely based on chart reviews; the company would have received $2.1 billion less if it had deleted unsupported billing codes, the government says.

The government argues that UnitedHealth Group knew that many conditions it had billed for were not supported by medical records but chose to pocket the overpayments. For instance, the insurer billed Medicare nearly $28,000 in 2011 to treat a patient for cancer, congestive heart failure, and other serious health problems that weren’t recorded in the person’s medical record, DOJ alleged in a 2017 filing.

In all, DOJ contends that UnitedHealth Group should have deleted more than 2 million invalid codes.

Instead, company executives signed annual statements attesting that the billing data submitted to CMS was “accurate, complete, and truthful.” Those actions violated the False Claims Act, a federal law that makes it illegal to submit bogus bills to the government, DOJ alleges.

The complex case has featured years of legal jockeying, even pitting the recollections of key CMS staff members — including several who have since departed government for jobs in the industry — against those of UnitedHealthcare executives.

‘Red Herring’

Court filings describe a 45-minute video conference arranged by then-CMS administrator Marilyn Tavenner on April 29, 2014. Tavenner testified she set up the meeting between UnitedHealth and CMS staff at the request of Larry Renfro, a senior UnitedHealth Group executive, to discuss implications of the draft rule. Neither Tavenner nor Renfro attended.

Two UnitedHealth Group executives on the call said in depositions that CMS staffers told them the company had no obligation at the time to uncover erroneous codes. One of the executives, Steve Nelson, called it a “very clear answer” to the question. Nelson has since left the company.

For their part, four of the five CMS staffers on the call said in depositions that they didn’t remember what was said. Unlike the company’s team, none of the government officials took detailed notes.

“All I can tell you is I remember feeling very uncomfortable in the meeting,” Rice said in her 2022 deposition.

Yet Rice and one other CMS staffer said they did recall reminding the executives that even without the chart review rule, the company was obligated to make a good-faith effort to bill only for verified codes — or face possible penalties under the False Claims Act. And CMS officials reinforced that view in follow-up emails, according to court filings.

DOJ called the flap over the ill-fated regulation a “red herring” in a court filing and alleges that when UnitedHealth asked for the April 2014 meeting, it knew its chart reviews had been under investigation for two years. In addition, the company was “grappling with a projected $500 million budget deficit,” according to DOJ.

Data Miners

Medicare Advantage plans defend chart reviews against criticism that they do little but artificially inflate the government’s costs.

“Chart reviews are one of many tools Medicare Advantage plans use to support patients, identify chronic conditions, and prevent those conditions from becoming more serious,” said Chris Bond, a spokesperson for AHIP, a health insurance trade group.

Whistleblowers have argued that the cottage industry of analytics firms and coders that sprang up to conduct these reviews pitched their services as a huge moneymaking exercise for health plans — and little else.

“It was never legitimate,” said William Hanagami, a California attorney who represented whistleblower James Swoben in a 2009 case that alleged chart reviews improperly inflated Medicare payments. In a 2016 decision, the 9th Circuit Court of Appeals wrote that health plans must exercise “due diligence” to ensure they submit accurate data.

Since then, other insurers have settled DOJ allegations that they billed Medicare for unconfirmed diagnoses stemming from chart reviews. In July 2023, Martin’s Point Health Plan, a Portland, Maine, insurer, paid $22,485,000 to settle whistleblower allegations that it improperly billed for conditions ranging from diabetes with complications to morbid obesity. The plan denied any liability.

A December 2019 report by the Health and Human Services Inspector General found that 99% of chart reviews added new medical diagnoses at a cost to Medicare of an estimated $6.7 billion for 2017 alone.

Save a valuable life

New Painkiller Could Bring Relief to Millions—Without Addiction Risk

New Painkiller Could Bring Relief to Millions—Without Addiction Risk

https://www.scientificamerican.com/article/new-pain-medication-suzetrigine-prevents-pain-signals-from-reaching-brain/

The medication initially known as VX-548 blocks sodium channels in nerves, blocking pain signals before they reach the brain

hen doctors ask Sara Gehrig to describe her pain, she often says it is indescribable. Stabbing, burning, aching—those words frequently fail to depict sensations that have persisted for so long they are now a part of her, like her bones and skin. “My pain is like an extra limb that comes along with me every day.”

Gehrig, a former yoga instructor and personal trainer who lives in Wisconsin, is 44 years old. At the age of 17 she discovered she had spinal stenosis, a narrowing of the spinal cord that puts pressure on the nerves there. She experienced bursts of excruciating pain in her back and buttocks and running down her legs. That pain has spread over the years, despite attempts to fend it off with physical therapy, anti-inflammatory injections and multiple surgeries. Over-the-counter medications such as ibuprofen (Advil) provide little relief. And she is allergic to the most potent painkillers—prescription opioids—which can induce violent vomiting.

Today her agony typically hovers at a 7 out of 10 on the standard numerical scale used to rate pain, where 0 is no pain and 10 is the most severe imaginable. Occasionally her pain flares to a 9 or 10. At one point, before her doctor convinced her to take antidepressants, Gehrig struggled with thoughts of suicide. “For many with chronic pain, it’s always in their back pocket,” she says. “It’s not that we want to die. We want the pain to go away.”

Gehrig says she would be willing to try another type of painkiller, but only if she knew it was safe. She keeps up with the latest research, so she was interested to hear earlier this year that Vertex Pharmaceuticals was testing a new drug that works differently than opioids and other pain medications.

That drug, a pill called VX-548, blocks pain signals before they can reach the brain. It gums up sodium channels in peripheral nerve cells, and obstructed channels make it hard for those cells to transmit pain sensations. Because the drug acts only on the peripheral nerves, it does not carry the potential for addiction associated with opioids—oxycodone (OxyContin) and similar drugs exert their effects on the brain and spinal cord and thus can trigger the brain’s reward centers and an addiction cycle.

In January Vertex announced promising results of clinical trials of VX-548, which it is calling suzetrigine, showing that it dampened acute pain levels by about one half on that 0-to-10 scale. The company is applying for U.S. Food and Drug Administration approval for the drug this year.

Other pain drugs that target sodium channels are now being developed, some by firms motivated by Vertex’s success. Navega Therapeutics, led by biomedical engineer Ana Moreno, is even using molecular-editing tools such as CRISPR to suppress genes involved in chronic pain. “We are definitely hopeful that we can replace opioids, and that’s the goal here,” she says.

One in five U.S. adults—51.6 million people as of 2021—is living with chronic pain. New cases arise more often than other common conditions, such as diabetes, depression and high blood pressure. Yet pain treatments have not kept pace with the need. There are over-the-counter pills such as aspirin, acet­aminophen (Tylenol) and nonsteroidal anti-inflammatories (NSAIDs) such as Advil. And there are opioids. The glaring inadequacy of existing medications to alleviate human suffering has fueled the ongoing opioid epidemic, which has led to more than 730,000 overdose deaths since its start.